3000 Pegasus Park Drive

Suite 1430

Dallas, Texas 75247

October 12, 2021


U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549


Attn:    Jane Park
Re:    Taysha Gene Therapies, Inc.
   Registration Statement on Form S-3 (File No. 333-260069)
   Request for Acceleration of Effective Date

Ms. Park:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-260069) (theRegistration Statement”) to become effective on October 14, 2021, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474, or in his absence, Asheley Walker at (202) 842-7856.

[Signature page follows]

Very truly yours,
Taysha Gene Therapies, Inc.

/s/ Kamran Alam

  Kamran Alam
  Chief Financial Officer


   RA Session II, Taysha Gene Therapies, Inc.
   Divakar Gupta, Cooley LLP
   Asheley Walker, Cooley LLP

Signature Page to Company Acceleration Request – S-3